-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Picture: On the far left, the vaccine consists of part of the receptor binding domain (RBD) of the spike protein, shown in dark blue, connected to a single domain antibody fragment that recognizes the major histocompatibility complex (MHC) protein of class II, orange Oval
Source: Novalia Pishesha, Boston Children's Hospital
Currently available COVID vaccines require cold storage and advanced production capacity, which makes them difficult to produce and distribute widely, especially in less developed countries
Researchers led by Dr.
In mice, the vaccine triggered a strong immune response to SARS-CoV-2 and its variants
Unlike the current COVID-19 vaccine, the new design is entirely based on protein, making many facilities easy to produce
"We can also connect the entire spike protein or other parts of the virus," Pishesha said
Targeting antigen presenting cells
Nanobodies are a key part of vaccine technology
Ploegh said that the current COVID-19 vaccine stimulates the production of spike protein at the injection site and may indirectly stimulate antigen presenting cells
He said: "But removing the middleman and talking directly with the antigen-presenting cells is much more efficient
In mouse experiments, the vaccine triggered a strong humoral immunity against SARS-CoV-2 and stimulated a large number of neutralizing antibodies against spike protein fragments
Manufacturing advantage
Since this vaccine is a protein, rather than a messenger RNA like Pfizer/Biotech and Moderna vaccine, it is more suitable for mass production
"We don't need a lot of the fancy technology and expertise needed to make mRNA vaccines," Hammond said
This may make it possible to produce vaccines in many locations around the world, which are close to where the vaccine is used
"The initial application may not be COVID-19," Ploegh said
This research was supported by the Harvard Society, the Swiss National Science Foundation, the Director of the National Institutes of Health Pioneer Award, and the European Virus Archives Global (EVAg) project
About Boston Children's Hospital
Boston Children's Hospital is the number one children's hospital in the U.
S.
News and World Report, and is the main pediatric teaching subsidiary of Harvard Medical School
.
It is the largest research institution in the world, headquartered in the Pediatric Medical Center
.
Since 1869, its discoveries have benefited both children and adults
.
Today, the Boston Children’s Research Community has 3,000 researchers and researchers, including 10 members of the National Academy of Sciences, 25 members of the National Academy of Medicine, and 12 Howard Hughes Medical Investigators
.
Boston Children's Hospital was originally a children's hospital with 20 beds, and now it is a comprehensive pediatric and adolescent medical center with 415 beds
.
For more information, please visit our answer blog and follow us on social media @BostonChildrens, @BCH_Innovation, Facebook and YouTube
.
-# # #
Magazine
Proceedings of the National Academy of Sciences
DOI
10.
1073/pnas.
2116147118
Article title
Class II mhc targeted vaccine triggers immunity to SARS-CoV-2 and its variants
Article publication date
2-November-2021
COI statement
Paul Rothlauf and Sean Whelan of the University of Washington received unrelated funding support in sponsored research agreements with Vir Biotechnology, AbbVie, and sAB therapeutics
.
The remaining authors declare no competing interests
.
